v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
6 Months Ended
Aug. 01, 2026
Aug. 02, 2025
Cash flows from operating activities:    
Net income $ 342.5 $ 372.7
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 188.5 168.3
Stock-based compensation 533.8 295.7
Amortization of acquired intangible assets 440.1 489.4
Change in fair value of contingent consideration liability 433.7 0.0
Change in fair value of forward stock purchase contract (131.0) 0.0
Restructuring related charges (gains), net 0.0 (14.0)
Deferred income taxes 38.7 (9.2)
Other expense, net 58.3 80.8
Changes in assets and liabilities, net of acquisitions:    
Accounts receivable (31.7) (423.3)
Prepaid expenses and other assets (333.7) (93.4)
Inventories 36.9 (54.5)
Accounts payable (333.6) (68.1)
Accrued employee compensation (40.1) (90.8)
Accrued liabilities and other non-current liabilities 41.9 140.9
Net cash provided by operating activities 1,244.3 794.5
Cash flows from investing activities:    
Purchases of technology licenses (5.0) (2.2)
Purchases of property and equipment (282.4) (166.3)
Proceeds from sales of property and equipment 0.0 27.3
Acquisitions, net of cash acquired (1,270.9) 0.0
Other, net 6.6 (30.1)
Net cash used in investing activities (1,551.7) (171.3)
Cash flows from financing activities:    
Repurchases of common stock (400.0) (540.0)
Proceeds from employee stock plans 57.5 51.1
Proceeds from issuance of preferred stock 2,000.0 0.0
Tax withholding paid on behalf of employees for net share settlement (365.2) (100.9)
Dividend payments to stockholders (107.7) (103.5)
Payments on technology license obligations (56.6) (54.3)
Proceeds from borrowings 998.9 1,198.6
Principal payments of debt (500.0) (790.6)
Other, net (25.5) (7.5)
Net cash provided by (used in) financing activities 1,601.4 (347.1)
Net increase in cash and cash equivalents 1,294.0 276.1
Cash and cash equivalents at beginning of period 2,638.8 948.3
Cash and cash equivalents at end of period $ 3,932.8 $ 1,224.4